TrialSignal
Clinical trial intelligence report
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT04707768
Status
COMPLETED
Phase
PHASE3
Sponsor
Akebia Therapeutics
Executive brief
Investment-Ready Snapshot
The trial evaluated the efficacy and safety of vadadustat, an oral treatment, compared to Mircera®, a long-acting erythropoiesis-stimulating agent, for maintaining hemoglobin levels in hemodialysis patients with anemia. The study enrolled 456 participants and was completed in January 2023.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT04707768
Indication
Anemia Associated With Chronic Kidney Disease (CKD)
Modality
small molecule
Target
Anemia associated with chronic kidney disease (CKD)
Intervention
Vadadustat, Mircera®
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.